Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 17;384(24):2354-2356.
doi: 10.1056/NEJMc2103022. Epub 2021 Apr 6.

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization

Guo-Lin Wang  1 , Zhuang-Ye Wang  2 , Li-Jun Duan  1 , Qing-Chuan Meng  3 , Ming-Dong Jiang  2 , Jing Cao  2 , Lin Yao  4 , Ka-Li Zhu  4 , Wu-Chun Cao  4 , Mai-Juan Ma  4
Affiliations

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization

Guo-Lin Wang et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralization of SARS-CoV-2 Pseudoviruses in Convalescent and Vaccinee Serum Samples.
Panel A shows the 50% pseudovirus neutralization titer (pVNT50) in convalescent serum collected from 34 recovered patients approximately 5 months after SARS-CoV-2 infection and in serum collected from 50 vaccinees who had received either the BBIBP-CorV or CoronaVac vaccine 2 to 3 weeks after the second dose against recombinant vesicular stomatitis virus–based SARS-CoV-2 pseudovirus bearing the Wuhan-1 (wild-type) spike protein. Box plots indicate the median and interquartile range (IQR); the whiskers represent 1.5 times the IQR. Panel B shows changes in the reciprocal serum pVNT50 titer in 34 convalescent serum samples against the D614G, B.1.1.7, and B.1.351 variants, as compared with wild-type virus. Panels C and D show changes in the reciprocal pVNT50 titer in serum samples obtained from the 25 recipients of the BBIBP-CorV vaccine and 25 recipients of the CoronaVac vaccine, respectively, against the D614G, B.1.1.7, and B.1.351 variants, as compared with wild-type virus. Factor changes in the geometric mean titer and 95% confidence interval (CI) in the pVNT50 titers, as compared with those for wild-type virus, are shown under the P values. Only P values of less than 0.05 (indicating significance) are shown. Each data point is the average of duplicate assay results. In each panel, the horizontal dashed line represents the lower limit of detection of the assay (titer, <30); this limit was assigned a value of 10 for geometric mean calculations and was considered to be seronegative. In all panels, calculations were performed with the use of the two-tailed Kruskal–Wallis test after adjustment for the false discovery rate.
See this image and copyright information in PMC

References

    1. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21:39-51. - PMC - PubMed
    1. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-192. - PMC - PubMed
    1. Huang B, Dai L, Wang H, et al. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. February 2, 2021. (https://www.biorxiv.org/content/10.1101/2021.02.01.429069v1). preprint.
    1. Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum — preliminary report. N Engl J Med. DOI: 10.1056/NEJMc2102017. - DOI - PMC - PubMed
    1. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021. March 8 (Epub ahead of print). - PubMed